Causeway Therapeutics

We are The Tendon Health Company, a clinical-stage biotech developing novel medicines for tendon disease. Tendinopathy represents a huge unmet need for millions of patients worldwide and is a significant cost to healthcare systems. Causeway has developed a proprietary microRNA mimic, microRNA29a, that acts through multiple pathways to treat chronic tendon disease. Causeway’s initial therapeutic focus is for treatment of lateral epicondylitis (tennis elbow), and the rotator cuff. TenoMIR restores tendon structure, reducing pain and improving function. It promises to transform patient outcomes and enable them to reclaim their active lives. Causeway is leading the race to launch the world’s first microRNA therapy.